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Several  non-invasive  imaging  techniques  are used to  investigate  the  effect  of pathologies  and  treatments
over time  in  mouse models.  Each  preclinical  in vivo  technique  provides longitudinal and  quantitative
measurements  of changes  in tissues and  organs,  which  are fundamental  for  the  evaluation of  alterations
in phenotype  due to pathologies,  interventions  and  treatments.  However,  it  is  still unclear how  these
imaging  modalities  can  be  used to study  ageing with  mice  models. Almost  all age related  pathologies  in
mice  such as  osteoporosis,  arthritis,  diabetes, cancer,  thrombi,  dementia, to name  a few,  can  be imaged
in vivo by  at  least one  longitudinal  imaging  modality. These measurements  are  the  basis for  quantification
of treatment  effects  in the  development  phase of a novel treatment  prior  to its  clinical testing.  Further-
more,  the non-invasive  nature  of such  investigations  allows  the  assessment  of different  tissue  and  organ
phenotypes in the  same animal and over  time,  providing the  opportunity  to study  the  dysfunction  of
multiple tissues associated  with  the  ageing  process.
This  review paper aims to  provide an overview  of the  applications  of the  most  commonly  used
in vivo  imaging modalities used in mouse studies: micro-computed-tomography,  preclinical magnetic-
resonance-imaging,  preclinical  positron-emission-tomography,  preclinical  single  photon  emission
computed tomography,  ultrasound, intravital microscopy, and  whole body  optical  imaging.
©  2016 The  Authors.  Published by  Elsevier Ireland  Ltd. This  is  an  open  access  article  under  the  CC  BY
license  (http://creativecommons.org/licenses/by/4.0/).
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1. Purpose of the review
1.1. Ageing mice and their application in preclinical research
Animal models, in particular mouse models, of human disease
have become a fundamental component of preclinical research.
Mice have a similar anatomy and physiology to  humans when
compared to other non-mammalian models such as drosophila
and zebrafish (Rosenthal and Brown, 2007). However, most impor-
tantly, many biological processes and pathways are conserved
between mice and humans including those most related to
metabolism and stress response, two of the overriding aspects of
disease progression. Additionally, mice and humans share over 95%
of  their genes, which paired with decades of genetic studies make
mice a formidable tool for the investigation of mammalian gene
function in health and disease (Justice et al., 2011; Rosenthal and
Brown, 2007). Murine models can allow researchers to investigate
the effect of pathologies and treatments in a more detailed manner
than it is possible in  clinical studies. Changes in tissues and can be
tracked organs over time, with high accuracy and non-invasively.
For a large body of human diseases, the primary or major risk factor
implicated in disease development is  ageing (Niccoli and Partridge,
2012). Age related diseases pose a  huge socio-economic burden
for both developed and developing nations. For example, in the
UK in 2013, the overall economic impact of dementia was 26.3
billion pounds and with analysts forecasting continued increases
in  ageing populations, the burden posed by these diseases is only
expected to rise (Prince et al., 2014; Suman and Beard, 2011). There-
fore, it is  sensible for researchers to move towards the use of aged
mice in order to better understand age related diseases. The term
“age related disease” covers an extremely broad field of study and
to  complement this, a  broad range of novel aged mouse models
will be required. Aged mice themselves are  a  relatively novel con-
cept and their use will yield a whole host of new challenges with
regards to their development, care and phenotyping. Addition-
ally, the high costs associated with the time required to develop
genetically modified models makes the choice of the appropriate
model fundamentally important (Benjamin et al., 2006). Extensive
systems are already in  place for the study of a huge number of  phe-
notypes in  mice (Ayadi et al., 2012; Ferruzzi et al., 2013; Hoit, 2004;
Lee et al., 2014; Raman et al., 2007; Rozman et al., 2014; Schofield
et al., 2012), but to  move forwards and tackle new challenges, scien-
tists rely on the continual development of novel technique that can
help them study and understand mice in increasingly robust and
efficient ways. One group of techniques that is playing an increas-
ingly important role in facilitating the use of aged mice models
is that based around in vivo imaging. Indeed, there is  a  growing
interest in applying in vivo imaging modalities to  study ageing in
laboratory mice, in order to acquire a  more comprehensive under-
standing of the mechanisms involved in the ageing process and
identify dysfunction of multiple tissues (Lin et al., 2014), to identify
biomarkers of early onset of age related diseases (Lai et al., 2004)
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and  to test novel interventions (Stodieck et al., 2014; Zhang et al.,
2015). These techniques can be used for providing both anatomical
and  functional information from the cellular level up  to  the whole
organism. Thanks to the improvement over the past years, some of
these modalities (e.g. functional or molecular imaging) have largely
increased their time and space resolution, being close now to phys-
ical limits of dose or field strengths. In vivo imaging can be applied
to study different aspects of ageing and the approaches presented
in this review can be combined in order to quantitatively charac-
terize the tissues and organ phenotypes longitudinally, leading to
a  comprehensive investigation of age-related dysfunction of mul-
tiple tissues. In addition, these methods applied to  mice models
have the potential of evaluating healthy ageing and frailty, which
are difficult to  assess in  humans, providing a  framework to test the
effect of novel interventions on several end points.
2. In vivo imaging techniques
2.1. Methods
This review focuses on the most commonly used in vivo imaging
techniques that can be applied pre-clinically to mouse models and
can be used for the study of ageing: micro computed tomography
(micro-CT), preclinical magnetic resonance imaging (preclinical-
MRI), preclinical positron emission tomography (preclinical-PET),
preclinical Single Photon Emission Computed Tomography (SPECT),
ultrasound (US), intravital microscopy and whole body optical flu-
orescence imaging. As the topic is  very broad and specific reviews
can be found with details about each technique, the goal of this
manuscript is to  provide an overview of the available imaging
modalities, without going into the details of the physics behind each
technique. In addition, we will highlight the potential for combin-
ing modalities and investigating the same animal longitudinally in
order, for example, to  study dysfunction of multiple tissues associ-
ated with ageing. In the following seven sections, the review aims
to underline the breadth of applications for the most used in vivo
imaging techniques, their main applications, potential and limita-
tions.
In Section 3 and Table 1 we report the advantages and limi-
tations of the application of such techniques to study ageing or
age-related pathologies in  mouse models.
2.2. Preclinical micro computed tomography (micro-CT)
2.2.1. Technique
Micro-computed tomography (micro-CT) is  an X-ray imaging
modality that allows the non-destructive analysis of the 3D archi-
tectural properties of an object. The sample or  animal to be  scanned
is placed between a microfocus X-ray tube, which emits X-rays
collimated and filtered to narrow the energy spectrum, and a  2D
charge-coupled device (CCD) array, which records the attenuated
X-Rays after passing through the scanned object. The object is
rotated during the scan and the projections taken in  each scan-
ning position are reconstructed into a  3D image. In the last two
decades, and with an achievable isotropic voxel size down to about
one micron, micro-CT has become the gold standard approach
for evaluating 3D micro-architectural properties of small animal
bones (Bouxsein et al., 2010). This imaging modality is  routinely
used ex-vivo,  in  endpoint animal studies of bone diseases, to pri-
marily assess the effect of interventions on bone health (Pierroz
et  al., 2010; Sugiyama et al., 2008). More recently, the use of
in-vivo micro-CT has proven extremely valuable in  monitoring,
non-invasively, spatio-temporal changes in  bone micro-structure
with age and/or disease (Fig. 1-A,B). It  has the advantage that, by
measuring the properties of the same bone, of the same animal, over
time, the quantities can be normalized with respect to  the baseline
values (Fig. 1-D), correcting for the intrinsic initial variability of the
animals assigned to different groups (Glatt et al., 2007; Silva et al.,
2012).
With voxel sizes down to 9 m,  this technique can measure
efficiently the size and distribution of small bone features such as
trabeculae. Moreover, once applied to the mouse, the whole verte-
brae (Lambers et al., 2012; Schulte et al., 2011) and long bones (Lu
et al., 2015a) can be scanned, guaranteeing more comprehensive
analyses in those specific anatomical sites.
2.2.2. Applications for mineralized tissues
In  vivo micro-CT has been already used in mice to study the effect
on the bone microarchitecture and density of musculoskeletal
pathologies related to ageing such as osteoporosis (Klinck and Boyd,
2008), fractures (He et al., 2011)  and bone metastases (Ravoori et al.,
2010). Furthermore, this technique has been used for studying the
effect of pharmacological treatments (Stadelmann et al., 2011) and
of external loading (Silva et al., 2012; Willie et al., 2013) on calci-
fied (hard) tissues. In  particular, Klinck and Boyd (2008) used in vivo
micro-CT scans of the proximal tibia for assessing the magnitude of
bone changes due to ovariectomy in different inbred mice  strains,
in  order to select the best mouse model of accelerated bone loss. In
two other studies, Silva et al. (2012) and Willie et al. (2013) investi-
gated the effect of in vivo mechanical loading of the mouse tibia on
the related longitudinal bone changes in  the trabecular and corti-
cal compartments, in function of ageing. Similarly, Stadelmann et al.
(2011) studied the effect of combined in vivo loading and injections
of zoledronate on the properties of the cortical bone of the mouse
tibia. Furthermore, He et al. (2011) have used in vivo micro-CT to
investigate bone healing in  a defect-induced mouse femur model,
showing the defect-closing rate on the same animals tracked over
time. Ravoori et al. (2010) showed how induced prostate cancer
affects the bone mineral density in a mouse model by  using low res-
olution in vivo micro-CT. Moreover, if coupled with advanced image
processing techniques, such as image registration, in-vivo micro-CT
imaging can improve the precision of bone parameter measure-
ments, therefore increasing the sensitivity to detect changes in the
bone micro-architecture following intervention (Baiker et al., 2011;
Campbell et al., 2014). This technique can also provide low resolu-
tion scans of the whole skeleton (Fig. 1-C1) and high resolution
scans of the whole bones in vivo (Fig.  1-C2,C3,C4), and allows users
to generate subject specific computational models for non-invasive
estimation of bone strength as well as local mechanical properties
associated with ageing (Lambers et al., 2012, 2015; Razi et al., 2015)
or different interventions (Levchuk et al., 2014; Willie et al., 2013;
Yang et al., 2014).
2.2.3. Applications for soft tissues
Although bone imaging is  the most common in vivo micro-CT
application, increasing evidence shows that non-mineralized (soft)
tissues can also be  imaged, provided there is sufficient contrast
between the tissue of interest and the surrounding areas (Bouxsein
et al., 2010).  These methods allow micro-CT to be used for the study
of some soft tissues related to pathologies such as, for example,
osteoarthritis, atherosclerosis and lung tumours. Many soft tissues
have been scanned ex  vivo with or without contrast agents: soft tis-
sue of the paw (Perilli et al., 2015), angiogenesis (Gayetskyy et al.,
2014)  and cartilage (Marenzana et al., 2014)  are examples. How-
ever, only a  few of these procedures are applicable in vivo. One
approach is to use the intrinsic heterogeneity of the native contrast
that some tissues possess, as for lung imaging or adipose tissue. For
example, the lung tissue has the particularity of presenting a good
contrast with the air it is filled with. In vivo lung imaging, com-
bined with custom image processing algorithms, provides a  good
tool to study lung function in  acute and chronic small animal pul-
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Table 1
Summary of the specifications, main advantages and main limitations of the  preclinical in vivo imaging techniques presented in this review, with particular emphasis on the  applications for studying ageing or age-related diseases
with  mouse models.
Preclinical
In vivo imaging
modality
Imaging Time Maximal resolution Advantages Disadvantages Main Longitudinal applications
associated to  ageing and
age-related diseases
Examples
Micro CT min-h ∼0.01  mm  (organ)
∼0.1 mm (body)
Very good spatial resolution
Good sensitivity
Long scanning time
Potential moving artifacts
Radiation exposure
Limited number of contrast
agents for in vivo applications
Osteoporosis and remodeling
Bone metastasis
Neurodegenerative diseases
Lung and liver tumour
progression
Bone regeneration (combined
with SPECT)
Klinck and Boyd (2008);  Silva et  al.,
(2012);  Willie et al.  (2013)
Ravoori et al. (2010)
Starosolski et  al.  (2015)
Lalwani et  al.  (2013)
Ohta et al. (2006)
He  et al. (2011);
Lienemann et  al. (2015)
Micro MRI min-h ∼0.1 mm
(in plane)
Good spatial resolution
Contrast agents can  be used
Long scanning time
Potential moving artifacts
Poor  sensitivity (can  be
improved with contrast agents)
Alzheimer’s disease
Cardiac structure and function
Decreased brain function
Maheswaran et  al.  (2009)
Schneider et  al. (2008)
Sorond et  al. (2011)
PET min  ∼1  mm High sensitivity
Many radiotracers
Poor spatial resolution
Requires specialized
radiochemistry
Radiation exposure
Alzheimer’s disease
Parkinson’s disease
Atherosclerosis
Type  2 diabetes
Fodero-Tavoletti et al. (2011)
Waerzeggers et al. (2010)
Wenning et  al. (2014)
Yong et al. (2011)
SPECT min  ∼1  mm Good  sensitivity (lower than
PET)
Fewer radiochemicals
compared to  PET
Radiation exposure
Parkinson’s disease
Alzheimer’s disease
Oncology
Bone regeneration (combined
with microCT)
Hwang et  al. (2002)
Shimizu et al. (2016)
Bernsen et al. (2014)
Lienemann et  al. (2015)
Ultrasound s  0.5  mm (3 MHz)
0.15 mm (10 MHz)
Great temporal resolution.
Portable
no long-term side effects
Relatively cheap
Poor depth-of-field for high
resolution imaging (high
frequency).
Poor bone and air penetration.
The method is
operator-dependent
Liver diseases
Cardiac fibrosis
Hydronephrosis
Fernandez-Dominguez et al.  (2011)
Johnson et  al. (2013)
Springer et al. (2014)
Optical
intravital
microscopy
s  <0.01 mm Real time imaging
Very high resolution
Good sensitivity
Many  contrast agents
Relatively cheap
2D technique requires surgery Cortical plasticity
Beating heart
Atherosclerosis and myocardial
infarction
Stodieck et al. (2014)
Vinegoni et al. (2015)
Swirski and Nahrendorf (2013)
Whole body
optical imaging
s-min ∼0.1 mm (organ)
∼1  mm (body)
High sensitivity
Many fluorescent markers
available
Relatively cheap
In most cases  still  2D technique
Requires genetically modified
tumour cells
Nude or shaved animals
required
Alzheimer’s disease
Diabetes, Hypertension
Osteoarthritis
Tumour vasculature
Lin et al. (2014)
Hall et al. (2012)
Lai et al. (2004)
Pesnel et al. (2012)
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Fig. 1. Examples for in  vivo micro-CT imaging: A) The Scanco Viva80 is  an example of a commercially available in  vivo micro-CT (courtesy of Scanco Medical AG). B) Particular
of  the scanning area and of the mouse holder with the sensors used to monitor the mouse status during the scan. Different images can  be obtained with this system for
analyses of bones: C1, low  resolution scan and 3D reconstruction of the whole mouse skeleton and soft tissues. Scans were performed with 71.8 m voxel size, 55 KeV voltage,
145  A current, and 20 ms integration time; C2, high resolution scan and 3D reconstruction of the whole mouse tibia. Scans were performed with 10.4 m voxel size, 55  KeV
voltage, 145 A current, and 200 ms  integration time; C3-4, Cross sections of the reconstructed trabecular and cortical regions from  C2. D: Example of analyses of longitudinal
changes  in trabecular bone  volume fraction (BV/TV) with respect to baseline (week 0) with scans performed every week for ovariectomized (Ovx, N =  7)  and sham operated
(Sham, N = 4) 14 weeks old  C57BL/6J female mice (unpublished data).
monary disease models when combined with respiratory gating
(Artaechevarria et al., 2009; Johnson, 2007). This method can also
be applied for monitoring the progression of lung tumours (Li et al.,
2013; Rodt et al., 2009). Moreover, in vivo imaging of adipose tissue
using micro-CT provides more details compared to  2D dual energy
X-ray absorptiometry (DXA) and was found to be as accurate yet
more cost and time effective than preclinical-MRI in assessing body
composition and discriminating between adipose and non-adipose
tissue (Luu et al., 2009; Wyatt et al., 2015). Another approach to
visualize the target tissue is the use of contrast agents (Lusic and
Grinstaff, 2013). For instance, in vivo contrast-enhanced micro-CT
has been used to monitor liver tumours progression (Ohta et al.,
2006), to evaluate rodent models of hepatic/brain ischemia and
stroke (Hayasaka et al., 2012), to evaluate cartilage degeneration
in rats (Piscaer et al., 2008), and to quantify vasculature in mice
(Nebuloni et al., 2014; Starosolski et al., 2015). Finally, nanopar-
ticles as contrast agents were used in  an in vivo micro-CT setting
to monitor tumour vasculature (Ghaghada et al., 2011), and the
progression of lung tumours (Lalwani et al., 2013).
2.2.4. Summary of advantages and limitations
The main advantage of in vivo micro-CT imaging is the high
penetration depth of X-rays through the different tissues, which
leads to the high image resolution (voxel size down to 8–10 m),
enabling accurate longitudinal measurements of anatomical fea-
tures, of bone or  stained soft tissues. The great potential of  in vivo
micro-CT is  also its ability to  be coupled with other in vivo imag-
ing modalities such as preclinical-PET in order to evaluate for
example carcinogenesis and treatment strategies in  circumscribed
lung tumours (Rodt et al., 2009), and optical imaging to monitor
for example the dynamic changes in bacterial burden, neutrophil
recruitment and bone damage in  a  mouse orthopaedic implant
infection model (Niska et al., 2012). More details about these tech-
niques will be provided in the next sections.
Despite its advantages, in vivo micro-CT imaging has a num-
ber of limitations. First, being an X-ray based imaging modality;
the associated radiation dose to which the animal is exposed dur-
ing scanning is an important factor to consider as it could affect
the measurements. Several studies have assessed the impact of
successive imaging on the organ or tissue integrity and function.
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It appears that the radiation affects differently soft and hard tis-
sues and a number of studies have been performed to  reach the
best compromise between image quality and radiation dose (Klinck
and Boyd, 2008; Laperre et al., 2011; Vande Velde et al., 2015).
However, there is not yet general consensus about standardized
scanning protocols for the different anatomical sites and there is
no way to estimate the effective radiation dose (i.e. the tissue-
weighted sum of the equivalent radiation dose in all tissues and
organs of the body during the scan) in  the mouse. Consequently,
in order to reduce the scanning time and therefore the radiation
dose, in vivo analyses are usually performed with lower resolution
(9–15 m for bone) compared to ex vivo imaging (down to 1–5 m
for bone), with a  resulting decreased precision when measuring
small features of  mouse bones (e.g. average trabecular thickness in
the proximal tibia is  approximately 40–60 m).  A second limita-
tion is related to motion artifacts: with micron level resolutions,
any movement of the animal while under anaesthesia will lead to
motion artifacts on the acquired images. To minimize them, spe-
cial  holders are provided by  the manufacturers to ensure the target
organ/tissue is well placed and maintained. However, they cannot
be completely removed in  particular when central sites (e.g verte-
brae, lungs) are scanned. Additionally, animal wellbeing must be
monitored at all times, increasing the complexity of the scan and
the costs associated with it.  Under general anaesthesia, mice are
unable to maintain normothermia (with a  drop in  core tempera-
ture of 1 ◦C every 4 min  for a C57Bl6 mouse) (Caro et al., 2013). It
is therefore imperative to add a heating system in  order to main-
tain the animal’s temperature as close as possible to normothermia.
Breathing pattern should also be  monitored carefully, to minimize
any discomfort to the animal, but also to minimize the risk of move-
ment artifact (gasping, unsteady breathing pattern). When properly
monitored, a mouse can be maintained under anaesthesia for up to
4 h, with fast recovery and no apparent short term effect (Lu  et al.,
2015a).
2.3. Preclinical magnetic resonance imaging (MRI)
2.3.1. Technique
Magnetic resonance imaging (MRI) utilises a  strong magnetic
field to polarise the magnetic moments of specific nuclei within the
subject. This generates a  significant equilibrium net magnetisation.
Radio frequency coils are used to transmit short electromagnetic
pulses to perturb this magnetisation. As the magnetisation relaxes
back to the equilibrium position a decaying oscillatory electrical
current is induced in  the radio frequency antennae. To spatially
localise the signal in  three dimensions, powerful magnetic gradi-
ent  coils are used to  encode these oscillating signals in  terms of
their frequency and phase. These electrical signals are interpreted
(via Fourier transform) into an image with different tissues having
different signal amplitudes and decay rates. The amplitude of the
signal is primarily affected by  the nuclei density within the tissue.
The decay rate is indicative of two different physical effects; i) the
transfer of energy from the nuclear spin system to  adjoining/lattice
molecules and ii) the loss of phase of the oscillatory signal caused
by magnetic field in-homogeneities and direct interaction between
nuclei (without energy loss to  the surrounding lattice). As such MRI
has unparalleled soft tissue contrast and is now widely used in  age
related research in both human and animal studies. For a  more
detailed description of MR  theory the reader should consult the
existing literature [1–4].
Preclinical-MRI is  an ideal technique for the investigation of sev-
eral age related disease phenotypes; the main advantages being
that it offers in-vivo, high resolution, 3D, non-invasive images. The
latter importantly permits longitudinal studies using knockout and
control mice, a prerequisite for advancing age related research.
Furthermore, the preclinical-MRI technology used in  the preclin-
ical setting is identical to that already used in  hospitals worldwide
for diagnostic purposes but often provides smaller bore holes and
higher magnetic field strength. This means that promising new in
vivo biomarkers or treatment strategies involving preclinical-MRI,
for age related disease phenotypes, have the potential for direct
clinical translation.
2.3.2. Most common applications
The most commonly imaged nuclei in biological organisms are
the hydrogen protons contained within the abundant water pool.
The brain and heart (the most commonly imaged organs with MRI)
are composed of 73% water. Other tissues that are associated with
age related diseases, e.g. the muscles and kidneys are composed of
79% water (Mitchell et al., 1945). By imaging such tissues over time,
development of solid organ atrophy and other phenotypes can be
detected throughout the body. Since age is a major risk factor for
neurodegenerative disease, MRI  has been used extensively to mon-
itor structural changes within the brain, comparing pathological
measurements to normal age related changes.
Clinical MRI  studies have shown that the brain decreases in
total volume at an accelerated rate after the age of 50 (Craik and
Salthouse, 2000; Raz et al., 2005; Raz and Rodrigue, 2006) and vol-
umetric analyses with MRI  is  actively used in the diagnosis of  mild
cognitive impairment and Alzheimer’s disease; with an impressive
diagnostic accuracy of approximately 90% (Norfray and Provenzale,
2004). MRI  technology has also shown that white matter changes
are an effect of very old age (Raz et al., 2005; Salat et al., 1999;
Sowell et al., 2003)  whereas grey matter loss starts earlier and is
more gradual.
These gross structural changes have been replicated in nor-
mal and transgenic mice used in  ageing studies, using high field
MRI  (>7 T) that is commonly used in the pre-clinical setting
(Maheswaran et al., 2009). Although simple structural MRI alone
cannot define the causal pathway of these changes, it can help con-
firm that  new mouse models of ageing and associated diseases are
displaying the required pathology. Even though volumetric brain
analysis appears to be a  suitable metric of age related changes,
the power of MRI  really shines through when it is  used in  con-
junction with other pre-clinical techniques. For example animal
studies with electrophysiology and calcium dye imaging (Burke and
Barnes, 2006) have provided evidence that  deficit in  brain plastic-
ity (its ability to form new connections and memories) is  a  result
of age induced changes in calcium regulation. Changes in  calcium
regulation directly affect action potentials as they traverse axons
and thus change neuronal pathways. For a  full review the reader is
referred to Burke and Barnes (2006).
MRI  also has the potential for identifying such breakdowns in
cerebral networks directly, beyond measurements of gross struc-
tural deficits. Diffusion tensor imaging (DTI) gives a measure of
the magnitude and orientation of the diffusion of water (the stan-
dard proton signal source). With no  barriers, water is  free to move
in  any direction, diffusing isotropically. However the brain is full
of long neuronal bundles, which constrain the movement of the
water so that it tends to follow the long axis of the bundles (result-
ing in anisotropic diffusion). DTI-MRI measures the strength of  the
directional dependence of diffusion and therefore to  some extent
tissue disruption, the so-called fractional anisotropy (FA). If  the
neuronal bundles are disrupted the molecular motion will return
to its free diffusion state and lead to decreased FA. Studies using
DTI-MRI FA metrics suggest that the microstructure of  the white
matter integrity is different between normal and pathological age-
ing (Minoshima and Cross, 2008; Song et al., 2004). However, like
structural MRI  there is no global standard for DTI analysis, which
can drive over interpretation of results. It is  in the end only mea-
suring diffusion driven by axonal membrane integrity with myelin
playing a modulatory role (Beaulieu, 2002).
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Fig. 2. BOLD fMRI is  a  very qualitative and pseudo measure of neuronal activity. Only by  combing fMRI with other neuro-imaging techniques can one really understand
neurovascular coupling. Concurrent fMRI and optical imaging can be used to  investigate changes in the brain’s vascular response with age in rats (Kennerley et al., 2012).
BOLD  fMRI statistical activation maps in this topographic plane can be compared directly to complementary functional haemodynamic statistical maps from 2D-OIS. The
underlying micro-vasculature can be identified using optical imaging both inside the magnet and outside (without the endoscope).
Reproduced with permission from (Kennerley et al., 2012).
A surrogate measure of neuronal activity can be made using
functional MRI  (fMRI). fMRI relies on a process known as neurovas-
cular coupling, where localised changes in neuronal activity drive
changes in vessel diameter in order to control cerebral blood flow
and to supply the required substrates to  that region of the brain. The
tissue is often hyper-perfused which leads to an overall increase
in  cerebral blood oxygenation, making the relative percentage
of paramagnetic deoxyhaemoglobin lower. This homogenises the
local magnetic field and results in  an increase in MR  signal mag-
nitude –  the so-called Blood Oxygenation Level Dependent (BOLD)
fMRI signal (Kwong et al., 1992; Ogawa et al., 1990). Studies using
this technique in rats have shown a change in  the brain’s vascular
response with age (Dubeau et al., 2011). Subsequent breakdowns
in neurovascular coupling can lead to decreased function (Sorond
et al., 2011). BOLD fMRI by itself is a very qualitative measure and
only a pseudo-measure of neuronal activity. In order to investi-
gate if neuronal pathways break down and drive smaller changes in
the haemodynamics or if the vascular disruption limits delivery of
metabolites and cause cell death (Zlokovic, 2010), BOLD fMRI needs
to be coupled with other neuro-imaging techniques such as optical
imaging spectroscopy (Kennerley et al., 2012) (Fig. 2) and electro-
physiology (Pan et al., 2010). This coupling provides measurements
of changes in the haemodynamic response and neuronal response
respectively in animal models.
Following the vascular hypothesis for neurovascular coupling
breakdown as a  mechanism of decreased cognitive function and
development of neurodegenerative diseases, one could make a
causal link from early age cerebral hypo-perfusion and vascular
risk factors leading to white matter damage (Firbank et al., 2007;
Spilt et al., 2005). Recent studies have attempted to elucidate the
relationship between brain perfusion variability and risk  factors of
endothelial dysfunction and atherosclerosis in  healthy aged sub-
jects (Henriksen et al., 2014). It was concluded that the amino acid
homocysteine, increased amounts of which make a  person more
prone to endothelial cell injury and thus blood vessel inflammation,
may be a  marker of cerebral perfusion in  ageing brains. Magnetic
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resonance angiograms, where stationary tissue contrast is nulled
and only signal from flowing blood measured, could find use in the
assessment of such effects (Beckmann et al., 2003; Slawson et al.,
1998; Wiesmann et al., 2002, 2000).
Not only hydrogen nuclei in  water but also nuclei in other
molecules/metabolites exhibit magnetic resonance. This opens up
the possibility of studying ageing effects on cellular metabolism in
different organs. Importantly, the resonance frequency is  different
for each metabolite, which can therefore act as a  finger-print of
the relative concentrations of different target metabolites (Rudin,
1992), once the water signal is  nulled. Magnetic resonance spec-
troscopy (MRS) predates MRI, and as an analytical technique has
been applied to studies of ageing in  human (Robertson et al.,
2001) and in mice (Oberg et al., 2008; Yang et al., 2011). More-
over, Carbon-13 MRS  can be used for characterising fluxes and
pathways of metabolism. Using Phosphorus-31 MRS  one can inves-
tigate adenosine tri-phosphate synthesis directly (Pettegrew et al.,
1987). The problem is  that these nuclei have low abundance in  the
body and therefore signals are difficult to measure. A new tech-
nique involving hyperpolarisation of carbon-13 labelled metabolic
substrates, which can increase their MR  signal by 10,000 times
(Ardenkjaer-Larsen et al., 2003), has started a  resurgence in the field
of MRS. This technique has been used mainly for cancer research,
but it has also been applied to  investigate cardiac metabolism
(Aquaro et al., 2013) – dysfunction of which is  related to the ageing
brain.
2.3.3. Summary of advantages and limitations
Preclinical-MRI is  an ideal technique for the investigation
of several age-related disease phenotypes; the main advan-
tages being that it offers in-vivo, relatively high resolution, 3D,
non-invasive images. The latter importantly permits longitudi-
nal studies using knockout and control mice, a prerequisite for
advancing age related research. Furthermore, this technique is  very
similar to its clinical counterpart, making the clinical translation
straightforward.
Limitations of MRI  are  the inherent low sensitivity and, due to
the size of the mouse compared to the human, the need  for high
field strength systems for pre-clinical studies. Most pre-clinical
MRI  centres employ MRI systems with field strengths of 7 T and
above. The high field increases the nuclear magnetic polarisation
and therefore the signal; in turn this can be sacrificed to  increase
the spatial resolution to  achieve a  good standard in  the pre-clinical
model. The small size of the mouse also necessitates the use of
stronger imaging gradients (typically around 300+ mT/m in  mice
compared to 30+ mT/m in human) to enable to system to achieve
these higher resolutions. In essence, both clinical and preclinical
systems are superconducting solenoids surrounded by  a  helium
cryostat. Preclinical systems only differ in  their reduced bore size
(to make the engineering of the higher fields and gradients easier).
With this advanced/miniaturised technology comes a  hefty price
tag with pre-clinical MRI  systems often on a  par with their clini-
cal counterparts. It might be naively presumed that the higher the
field strength, the better for mouse imaging. However, although
the polarisation (and hence signal) increases, the field becomes
increasingly more difficult to homogenise (images appear dis-
torted) and the relaxation times of the MR  signal decrease with
increased field strength. This means that image contrast changes
and data must be captured in shorter echo time periods (Duyn,
2012). The choice of field strength must always be informed by
the proposed application. For example, a  reduced field strength is
advised for imaging the pulmonary system to  ensure relaxation
times are long enough to capture data. For functional MRI, field
strengths around 7–9.4 T are optimal for a balance between signal
and image distortions with fast echo planar imaging. For these rea-
sons, low field strength (<7 T) benchtop permanent magnet imaging
systems are becoming common-place to complement high field
superconducting systems. These are cheaper, smaller and do not
require expensive cryogenics or  cooling systems. For this reason,
as this technique develops, one might see a separation of clinical
and preclinical-MRI techniques – whether this be an advantage or
disadvantage remains to  be seen. There are also other limitations
related to  the handling of living animals during the scanning pro-
tocol, especially within the very small bores of high field strength
systems. The animal is  usually anaesthetised by using gaseous
isoflurane, levels of which are incredibly difficult to  stabilise when
all monitoring equipment has to  be non-magnetic and by neces-
sity is  viewed remotely outside the scanner room. Breathing rate
is often the only metric one has to assess the levels and this can
change rapidly in a  mouse. It  can also be a challenge to  keep the
animals warm within the cold bore of a  superconducting magnet.
Different centres have very different strategies, employing hot  air,
heating blankets or  water based systems, sometimes without tem-
perature control feedback. Any slight changes in basic physiology
(which could also be  different between knockout groups and con-
trols) could be a  major contributing factor in result variation and
can be incredibly to  control for. Schneider et al. (2008) attempted
to  use cine-MRI for determining global cardiac function longitudi-
nally in guanidinoacetate N-methyltransferase (GAMT) knockout,
and wild type littermate mice. They soundly hypothesized that  lack
of creatine in GAMT knockouts would be  detrimental for resting
cardiac performance during ageing. However, they found no phys-
iologically significant differences in cardiac function between wild
type and GAMT knockout mice at any time point, perhaps reflect-
ing some comprehensive adaptation in the knockouts to account
for lack of creatine or again that changes in physiology masked
the results. Although perhaps a perplexing negative result, the
study was the first to report on the longitudinal investigation of
a transgenic mouse model using cardiac MRI  over the period of
one year. This application demonstrates the power of the technique
to accurately quantify cardiac functional parameters in  genetically
modified mice in  a  longitudinal fashion and start to  address the link
between cardiac and brain ageing.
2.4. Preclinical positron emission tomography (preclinical-PET)
2.4.1. Technique
Positron emission tomography (PET) can visualize the distribu-
tion and concentration of radiolabelled molecules injected into the
subject and can be used to monitor, in vivo, biological processes
such as enzymatic reactions, cellular metabolism, cell proliferation
and migration (Phelps, 2000). Its preclinical version is a potent
imaging modality for the investigation of age related diseases
in vivo in  mouse models. PET offers a  high sensitivity and specificity
for most imaging applications.
The spatial resolution of preclinical PET systems should ideally
compensate for the smaller organ sizes in  mouse models compared
to humans. Thanks to advances in light detector technology, sys-
tems with spatial resolutions in  the order of 1.5 mm to 1.6  mm
(Balcerzyk et al., 2009; Bao et al., 2009) and below, some resolving
structures smaller than 1 mm in  size (Bergeron et al., 2014; Nagy
et al., 2013), are now commercially available. It is even possible to
resolve structures as small as 0.7–0.8 mm using some research sys-
tems (Espan˜a et al., 2014; Weissler et al., 2015). However, this is
still a relatively low resolution when considering the small size of
mice. Unfortunately, time-of-flight PET (ToF-PET) does not signif-
icantly improve the image quality of preclinical imaging directly,
but a  good timing resolution still allows users to reduce the random
coincidences rate (Strother et al., 1990). Recently, ToF-PET benefits
were imaged for phantom diameters equivalent to  the size of  a  rab-
bit on a  research system with a  timing resolution of about 260 ps but
could not be shown for mouse-sized activity distributions (Schug
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et al., 2015a), that  would need a further improvement of timing
resolution (below 100 ps).
As most PET tracers only allow acquisition of functional infor-
mation, PET is often combined with a  second imaging modality to
provide an anatomical reference image. The combination of PET and
computed tomography (CT) is  commonly used in clinics as well as
for preclinical applications. Here, the two modalities image the sub-
ject sequentially and not  at the same time (Fig. 3A). PET integrated
into an MRI  system, on the other hand, offers real simultaneous
image acquisition allowing for excellent spatial as well as tempo-
ral co-registration if the interference between the two modalities
can be reduced to an acceptable level (Schug et al., 2015b; Wehner
et al., 2015; Weissler et al., 2015) (Fig. 3B).
Many age related diseases can be studied with the help of mouse
models. We  discuss a  few of the most common diseases with
focus on the PET imaging possibilities and challenges. Examples
of prominent diseases are picked from the fields of neurodegener-
ative, cardiovascular, and metabolic diseases and cancer without
claiming to give a  full overview.
2.4.2. Neurodegenerative diseases
Dementia is a disease strongly related to  ageing with
Alzheimer’s disease (AD) being the most common form. The patho-
logical features in  the AD brain include amyloid- (A)  plaques
which can be imaged with PET (Nordberg, 2004). An established
method for in vivo evaluation of A-plaque burden in  the human
brain is PET using the Pittsburgh compound-B (PiB) (Ikonomovic
et al., 2008; Klunk et al., 2004). Recent technical improvements in
preclinical PET systems allowed a  successful translation to mouse
models, including a  gain in  spatial resolution (Manook et al.,
2012) (Fig. 3C). Besides imaging of A plaques, tau is  a  further
promising target in  early AD diagnosis. Neurofibrillary tangles are
primary markers of AD and represent aggregates of the hyper-
phosphorylated tau protein. A novel tau-targeting PET radiotracer
is  [18F]THK523 has shown very promising results in preclinical
(Fodero-Tavoletti et al., 2011) and clinical studies (Okamura et al.,
2014).
Parkinson’s disease (PD) is  another common neurodegenerative
disorder related to ageing, mainly affecting the motor system. In
later stages of the disease, thinking and behavioural problems may
arise. PD has been investigated in toxin-induced and genetic models
(Bové et al., 2005; Fleming et al., 2005; Melrose et al., 2006). Using
recent preclinical PET systems it has become feasible to study PD
using [18F]DOPA in vivo in  e.g. weaver mutant mice (Sharma and
Ebadi, 2005; Waerzeggers et al., 2010).
In general, for detailed investigations of neurological activity
and diseases using preclinical PET the spatial resolution of the
image is a crucial performance parameter. With state-of-the-art
systems it is possible to resolve individual regions of the mouse
brain which enables e.g. the imaging of changes in  brain activity
using [18F]fluorodeoxyglucose (FDG).
For  multimodal imaging of neurodegenerative diseases,
preclinical-PET and preclinical-MRI is  the preferred combination
because preclinical-MRI provides an anatomic reference image
with excellent soft-tissue contrast to morphologically describe the
pathologic alterations and also allows measuring their impact on
neuronal activity and connectivity (Jack et al., 2010; Logothetis
et al., 2001).
2.4.3. Cardiovascular diseases
Atherosclerosis is a chronic age related disease that remains
asymptomatic for decades and is  the principal cause of heart attack,
stroke and gangrene of the extremities and responsible for 50%
of all mortality in the USA, Europe and Japan (Ross, 1993). It  is
often caused by high-risk plaques whose features may  show a thin
fibrous cap, large necrotic core, macrophage infiltration, neovascu-
larization, and intraplaque hemorrhage (Owen et al., 2011). In the
clinic, several of these features can be investigated using PET. For
example, FDG is  often used to identify inflammatory plaques rich
in macrophages (Rudd et al., 2002; Tawakol et al., 2006).
A wide range of animal models for atherosclerosis research
is available (Kapourchali et al., 2014). In general, they are most
useful to investigate the aforementioned features of plaques but
not so much to model the complications of atherosclerosis, such
as rupture and thrombosis (Cullen et al., 2003). While FDG PET
was used to  study atherosclerosis in  rabbits (Nie et al., 2016)
in order to predict plaque rupture (Aziz et al., 2008),  mice have
to be genetically modified in  order to develop atherosclerosis at
all because of a  very different fat metabolism. Most common is
the transgenic ApoE deficient mouse model, where mice develop
plaques in  dependence of their diet. In  this model plaque rup-
ture can be triggered by surgical ligation of the brachiocephalic
or carotid artery (Hartwig et al., 2015; Matoba et al., 2013). Using
ApoE deficient mice, it could be shown that FDG-PET is able to
distinguish shear-stress induced, inflamed atherosclerotic plaques
from non-inflamed plaques in vivo (Cheng et al., 2006; Wenning
et al., 2014). An even more accurate characterization of the inflam-
mation status in plaques may  be enabled using, amongst others,
the macrophage targeted probes [64Cu]TNP (Nahrendorf et al.,
2008)  or (LyP-1)4-dendrimer-
64Cu (Seo et al., 2014), the scavenger
receptor targeted probe 64Cu-CD68-Fc (Bigalke et al., 2014), 64Cu-
DOTA-vMIP-II binding to viral macrophage inflammatory protein
II (vMIP-II) (Liu et al., 2013) and the v3 integrin-targeted tracer
18F-galacto-RGD (Laitinen et al., 2009; Saraste et al., 2012).
2.4.4. Metabolic diseases
Diabetes mellitus (DM) type 1 is caused by a  loss of  the insulin-
producing -cells, which are  found in the pancreatic islets. DM
type 2 on the other hand is  characterized by insulin resistance.
PET is often used to  image the -cell mass and number which
is challenging in  mice in vivo because of the small dimensions
of the pancreas and the spotted location and considerably low
number of pancreatic islets. Furthermore, the pancreas is located
close to the kidney, which is the excretion organ of most PET
probes. Therefore, there is high demand for high spatial resolu-
tion to separate signals from both organs. Nonetheless, PET imaging
using [18F]fluorohydroxymethyl-butyl-guanine (FHBG) is sensitive
to  changes in -cell mass that precede the onset of diabetes (McGirr
et al., 2011). This has been shown in mouse models of diabetes type
1 and type 2 expressing multi-modality reporters for fluorescence
microscopy and in vivo bioluminescence imaging in their -cells.
These models nicely confirmed that the FHBG PET signal strongly
correlates with the -cell number and mass (Yong et al., 2011).
2.4.5. Tumours
The most frequent deadly disease related to ageing is cancer.
With a  higher age of the patient or animal, increasing instability of
the genome, decreased activity of the immune system and accu-
mulated environmental influences lead to a higher probability of
developing tumours.
As a quantitative whole body imaging modality and due to  the
availability of excellent radiotracers PET is  ideally suited for the
imaging of cancer, both for clinical and preclinical applications
(Gambhir, 2002). Multiple tracers have been used to  study glucose
metabolism ([18F]FDG), amino acid ([11C]methionine) and choline
([11C]choline) uptake, cell proliferation ([18F]FLT), inflammation
([18F]Galacto-RGD) and hypoxia ([18F]MISO). Among those FDG is
the most widely used radiotracer, because it is readily available
and has been shown to work effectively due to the high glu-
cose consumption of most malignant tumour cells (Vander Heiden
et al., 2009). Besides these purely diagnostic radiotracers targeting
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Fig. 3. Examples for preclinical hybrid PET imaging devices are  shown in A and B:.
A: The nanoScan® SPECT/CT/PET is  an example of a commercially available multi-modality preclinical imaging device (©MEDISO Medical Imaging Systems, courtesy of
MEDISO).
B:  The PET/MRI research insert “Hyperion-IID” is  shown mounted on  a standard patient table of a clinical 3T MRI  system (gantry cover removed). The system allows real
simultaneous image acquisition with both modalities (Adapted and reprinted from (Weissler et al.,  2015)). Examples for PET imaging of mice with neurodegenerative and
oncologic diseases are shown in C and D:
C: Alzheimer’s disease imaging in a mouse showing A-positive plaques in  vivo and ex vivo.  PET images are acquired with the tracer [11C]PiB. Corresponding autoradiography
and  fluorescence microscopy images confirm PiB binding to  plaque sites.
C1: [11C]PiB PET image. The low  resolution of PET does not allow identification of individual plaque sites but larger affected brain regions can  be seen. The width of color
scale represents 3 mm in reality.
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more general tumour mechanisms, there are  radiotracers which
are very closely linked to therapy and act as companion diagnos-
tics and theranostics. For example, the majority of lung cancers
are non-small-cell lung cancers (NSCLC) which are difficult to
treat. A small subset of NSCLC express mutations of the epider-
mal  growth factor receptor (EGFR), which are sensitive to tyrosine
kinase inhibitors, such as erlotinib (Wu et al., 2012). Thus, there is
a  demand for methods to select these patients for erlotinib ther-
apy and to exclude those who do not  express EGFR. This is  an
excellent example for the indication of personalized therapy and
a motivation to  develop companion diagnostics and theranostics.
In this context, the PET tracer [11C]-erlotinib was developed and
successfully evaluated in mouse models of lung cancer overex-
pressing EGFR (Li et al., 2007; Memon  et al., 2009). However, in
mouse models the strong accumulation of [11C]-erlotinib in the
liver sometimes made it difficult to identify basal lung cancer sig-
nals due to spillover effects especially on PET systems with a low
spatial resolution. As another example, older age is  one of the main
risk factors for prostate cancer. A wide range of mouse models is
used in prostate cancer research including xenograft and trans-
genic mouse models (Ittmann et al., 2013). For visualization with
PET, an 18F-labeled choline analogue ([18F]fluoromethyl-dimethyl-
2-hydroxyethyl-ammonium (FCH)) was successfully applied both
in humans and mouse models (DeGrado et al., 2000). Even bet-
ter results were obtained with recent PET-radiotracers targeting
prostate specific membrane antigen (PSMA). Of those 68Ga-labelled
PSMA showed excellent binding properties in  mice bearing LNCaP
tumour xenograft (Schäfer et al., 2012)  (Fig. 3D) as well as in
humans where it proved to be superior to  choline tracers (Afshar-
Oromieh et al., 2014). A further advantage of this compound
is that 68Ga can be replaced by  the therapeutic radioisotope
177Lu  and initial results in  tumour bearing mice as well as in
patients show promising therapeutic outcomes (Kratochwil et al.,
2015).
2.4.6. Summary of advantages and limitations
Preclinical-PET imaging of mouse models is  highly valuable for
the investigation of age related diseases as it offers high sensitivity,
specificity and a wide range of available tracers for various dis-
ease fields as for example neurodegenerative, cardiovascular, and
metabolic diseases and cancer (see Table 2 for a  selective overview).
The limiting factor of investigating mice with PET is, besides the
high cost and the handling with (sometimes fast decaying) radioac-
tive material, mainly the low spatial resolution which, however,
has seen constant improvement over the last years. In addition,
its limitations in  anatomical information can be compensated by
hybridizing PET with CT  or MRI. Finally, animal handling has a
big impact on the metabolism of a  mouse and FDG performed in
liver, brain and other organs can strongly vary dependent on the
metabolic state, activity and temperature of the animal. Anaesthe-
sia of animals should also be considered. Isoflurane is  well suited
for tumour-bearing mice. Ketamine/xylazine, on the other hand,
may  induce hyperglycemia (Fueger et al., 2006).
2.5. Preclinical single photon emission computed tomography
(preclinical-SPECT)
2.5.1. Technique
Single Photon Emission Computed Tomography (SPECT) detects
gamma  radiation that is directly emitted by a radionuclide during
decay. SPECT is similar to  conventional nuclear medicine planar
imaging by a  gamma  camera, but is able to provide 3D information
by acquiring multiple 2D-images while rotating around the imaged
object.
Due to the physical principle of SPECT-imaging, it is neces-
sary to implement collimators in SPECT-scanner systems to gain
spatial information of the gamma  decay. Collimators absorb pho-
tons that are not within a  small angular range. For  small animal
research pinhole or multiple-pinhole collimators are usually used
(Van Audenhaege et al., 2015), which provide a high spatial reso-
lution (preclinical-SPECT). Resolutions <1 mm can be achieved by
replacing clinical standard collimators (resolution 6–8 mm),  such as
parallel-hole, fan-beam and cone-beam collimators, with a  pinhole
collimator (Acton and Kung, 2003).
2.5.2. Applications
SPECT has a  wide range of applications due to different avail-
able tracers and, therefore, offers many options to image the ageing
mouse. The main ageing-related applications are myocardial perfu-
sion, neurodegenerative diseases, oncology and bone metabolism.
The risk of a  myocardial infarction increases with age. Using
99mTc-Sestamibi Wollenweber et al. (2010) showed the ability
of cardiac perfusion preclinical-SPECT to  detect myocardial per-
fusion defects in mice. The infarct volumes measured by SPECT
correlated highly with the results of gold-standard histology. Fur-
thermore, transgenic mice with overexpression of the EP3 receptor
leading to cardiac hypertrophy showed a  lower cardiac uptake of
99mTc-Sestamibi compared to  wild type mice (Pissarek et al., 2009).
Further tracers for measuring cardiac function are 99mTc-TETRO
(Vrachimis et al., 2012) and 123I MIBG (Dimitriu-Leen et al., 2015).
Neurodegenerative diseases, such as Parkinson’s disease and
Alzheimer’s disease, and other forms of dementia can also be eval-
uated with preclinical SPECT. Several SPECT-tracers are available to
image Parkinson’s disease: 99mTc-TRODAT-1 and 123I  FP-CIT bind
to  dopamine transporters (DAT), which in healthy people and mice
are strongly expressed in striatum and reduced in  this disease
(Hwang et al., 2002). Accurate detection of losses of approximately
60–80% striatal DAT after injection of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) was  found using the tracer 123I  FP-CIT
(Andringa et al., 2005). However, the tracer did not permit an
accurate evaluation of the nigral dopaminergic cells in  Parkinson’s
disease (Alvarez-Fischer et al., 2007). To differentiate between idio-
pathic Parkinson’s syndrome and atypical Parkinson’s syndromes
(multiple system atrophy, progressive supranuclear palsy), the
dopamine D2  receptor ligand 123I IBZM is used in clinical routine
(Heinzel et al., 2015). 123I IBZM is also an appropriate tracer for D2-
receptor SPECT in healthy mice (Meyer et al., 2008; Pissarek et al.,
2009).
C2: Digital [3H]PiB ex  vivo autoradiograph showing the PiB binding sites in high-resolution which allows to  distinguish individual plaque sites. The A burden is visualized
with  double immunofluorescence microscopy of A40 (green) and A42 (red) in C3 and with thioflavin S fluorescence (FITC excitation, cyan) in C4.
C5–7: Identical A plaque constellations of adjacent sections as marked by  white rectangle in C1–3. C5: magnification of digital autoradiograph as seen in C2. C6: corresponding
magnified view of A40/A42 stain as seen in C3. C7: Corresponding magnified view of Thioflavin S  stain as seen in C4.
The comparison of the PiB image nicely matches the fluorescence images indicating the specific binding of PiB (Adapted and reprinted from (Manook et al.,  2012)).
D:  PET imaging of a prostate cancer mouse model using a PSMA targeting tracer. After a dynamic preclinical-PET scan, a static scan was  performed 1  h post-injection. The
whole-body coronal preclinical-PET image of an athymic male nude mouse bearing an LNCaP tumour xenograft enables clear  identification of the prostate tumour site with
the kidney and bladder showing strong signals as well. The  graph showing organ activity as a  function of time demonstrates the excretion of the tracer by the  kidney, its
elimination from most organs and the persistent accumulation in  the tumour. After 1 h  the heart, muscle and liver background is  reduced, which allows measurement of a
clear  tumour signal. Thus, optimal timing (or even better kinetic analysis) is required to distinguish passive accumulation from active target binding (Adapted and reprinted
from (Schäfer et al., 2012)).
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Table 2
Selection of PET tracers used in clinical and preclinical applications.
Nuclide Tracer Fields of use
11C [11C]choline Prostate cancer diagnosis (alternative: [18F]FCH)
[11C]PiB A plaque burden; Alzheimer’s disease
[11C]methionine Amino acid transport; brain tumour diagnosis
[11C]Acetate Oxidative metabolism, fatty acid metabolism
15O 15O2 [
15O]Water Oxygen intake and distribution
Perfusion imaging
18F  [18F]FDG Glucose utilization; tumours, brain activity, inflammation (plaques)
[18F]FCH Prostate cancer diagnosis
[18F]FLT Cell proliferation; cancer diagnosis
[18F]MISO Hypoxia
[18F]DOPA Presynaptic dopaminergic integrity; Parkinson’s disease
[18F]THK523 tau targeting; Alzheimer’s disease
[18F]FHBG -cell imaging, Diabetes
[18F]Galacto-RGD Angiogenesis, inflammation; tumours, cardiovascular diseases,
[18F]NaF tumour metastasis and angiogenesis ( 3 expression)
Bone mineralization
68Ga [68Ga]PSMA Prostate cancer diagnosis
Dementia affects app. 40 million people, mostly older than 60
years, worldwide (Scheltens et al., 2016). Alzheimer’s disease is  the
most common form of dementia, followed by vascular dementia
and dementia with Lewy bodies. In this context, DAT-SPECT with
123I FP-CIT seems to  be an ideal method to accurately distinguish
between these pathologies (Shimizu et al., 2016). 99mTc-HMPAO-
SPECT is used in clinical practice to measure cerebral perfusion
(Heiss, 2014). However, it is  also a  promising technique for mea-
suring rCBF (regional cerebral blood flow) in  preclinical research
(Apostolova et al., 2012) and has been shown to depict age-related
changes during late maturation (juvenile and young adult) in  mice.
In contrast, 99mTc-ECD, another clinical tracer for cerebral perfu-
sion, is more difficult to  be applied in  mouse-brain SPECT because
of its fast tissue clearance (Apostolova et al., 2012).
In oncology, SPECT is frequently used to image neuroendocrine
tumors (NET) by using 111In-octreotide, and [177Lu-DOTA-Tyr3]-
octreotate for the visualization of somatostatin receptors (Bison
et al., 2015; Ullrich et al., 2016), to image thyroid cancer pre-
and post-therapeutically using 123I/131I-NaI (Liu et al., 2011; van
der Have et al., 2016) and to  perform bone scintigraphy. For  the
latter, the tracer 99mTc-MDP is used, which characterizes bone
metabolism in both degenerative changes and cancer (Cowey et al.,
2007; Lienemann et al., 2015). Multiple further tracers such as
111In-cCPE-GST, which binds to Claudin 4, that is  overexpressed in
several premalignant precursor lesions are available (Mosley et al.,
2015), but it would go over the scope of the article to provide a
complete overview (Bernsen et al., 2014; Cai and Li,  2013; Franc
et al., 2008).
2.5.3. Summary of advantages and limitations
The main advantage of SPECT is  that  it is  less cumbersome
and less expensive than PET. A wide range of tracers can be
used for both of these imaging modalities to  visualize differ-
ent functional information. SPECT even offers the possibility of
imaging multiple radio-labelled probes simultaneously. Energy dis-
crimination can be performed to differentiate between different
radioisotopes emitting gamma  rays at different energies. Many
radionuclides used for SPECT imaging can either be eluted from
generator-systems or  due to their intermediate half-lifes produced
in large amounts and distributed by pharmaceutical companies.
Even though SPECT does not provide morphological information,
it can be combined with CT  (SPECT-CT) or MRI  (SPECT-MRI) (Franc
et al., 2008).
On the downside, SPECT has a  reduced (10 times lower (Sandhu
et al., 2010)) sensitivity compared to PET in  both clinical and
preclinical settings (Rowland and Cherry, 2008), because lots of
radiation is  lost in  absorptive collimation. Furthermore, radiation
exposure cannot be disregarded, which is  particularly critical for
long-term observations of mouse models of ageing.
2.6. Ultrasound
2.6.1. Technique
Ultrasound is  a  mechanical wave operating usually between
2–30 MHz. Because ultrasound is a mechanical wave, there is no
ionizing radiation involved during the imaging of mice. During the
imaging procedure, the animals are lightly anesthetized with 1%
isoflurane and in order to  provide optimal ultrasound penetration
the hair is removed with a topical depilatory agent. The ultrasound
transducer is usually fixed in a  positioning device and acoustic cou-
pling through gel is made to  the mouse. High-frequency ultrasound
transducers produce high-resolution images of small structures,
ideal for detecting organ pathology in  mice. The role of ultrasound
imaging in  the ageing mouse lies mostly in  cardiac applications
(Kepez et al., 2008; Ram et al., 2011)  (Fig. 4). However, it has
recently been shown (Springer et al., 2014) to have a role  in assess-
ing  kidney pathology in mouse models.
2.6.2. Cardiac applications
Typical measurements provided by echocardiography in  mice
include chamber dimensions, wall thickness, and ejection fraction
(EF). These measurements are useful because one can determine
functional changes in  the heart caused by myocardial injury,
genetic modifications disease, drug treatments, and ageing (Ram
et al., 2011). Recently, myocardial strain measurements (Abraham
et al., 2007; Derumeaux et al., 2008; Friedberg and Mertens, 2013;
Springer et al., 2014) have been utilized to evaluate regional left
ventricular abnormalities that  are not normally explored with con-
ventional echocardiographic measurements.
The goal of the study performed by Rosenblatt-Velin et al. (2012)
was to  use stem cell antigen-1 (Sca-1) in  order to  identify cardiac
stem cells in the mouse heart using transthoracic echocardiogra-
phies, by using a 30-MHz transducer. In order to investigate the
function of the antigen in  ageing and during the cardiac adaptation
to stress, Sca-1-deficient mice were used. These mice developed
consistently dilated cardiomyopathy. Furthermore, the hearts of
mice lacking Sca-1 demonstrated exacerbated susceptibility to
pressure overload. The heart was imaged in  the 2D mode in the
parasternal long-axis view. From this view, M-mode ultrasound
was obtained measuring left ventricle (LV) free wall thickness in
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Fig. 4.  Examples for preclinical US  imaging setup (a)  and an example of US  image of abdominal imaging in mice (b).
diastole and in  systole as well as LV diameter in diastole and in
systole.
The natural ageing process results in the physiological decline
of multiple tissues and organ systems including the heart. Changes
commonly occur with middle age includes among others heart fail-
ure. Recent studies by Jackson et al. (2012) suggest that myostatin
may  influence cardiac output. In  this study an 18 MHz linear epicar-
dial transducer was used, while a  10 MHz-phased array transducer
was used for strain acquisition. Echocardiography was  performed
on anesthetized mice in  order to assess basal and maximal cardiac
performance using isoproterenol stress tests, which cannot be per-
formed on non-anesthetized mice as handling these mice induces
a stress response. Standard imaging planes, M-mode, Doppler,
and functional calculations were obtained. The left ventricle (LV)
parasternal long axis four-chamber view was used to derive ejec-
tion fraction (EF) as well as ventricular dimensions and volumes.
The left parasternal short axis view was used to obtain M-mode
ventricular wall measures, fractional shortening (FS), and for radial
strain analysis. Finally, the subcostal long axis view, from the left
apex, was used for Doppler imaging of mitral inflow and aortic
ejection profiles. Stress tests were performed after first obtaining
a baseline echocardiogram followed by i.p. injections of isopro-
terenol (10 mg/kg).
The commonly used anaesthetic agent, isoflurane, is a  potent
coronary vasodilator which could potentially be used in the assess-
ment of coronary reserve, but its effects on coronary blood flow
in  mice are unknown. Coronary reserve is  reduced by age, coro-
nary artery disease, and other cardiac pathologies. In  the study
by Hartley et al. (2007) Doppler ultrasound was used to mea-
sure coronary flow velocity in mice anesthetized at low (1%) and
at high (2.5%) levels of isoflurane to  generate baseline (B) and
elevated hyperemic (H) coronary flows respectively. A  20 MHz
Doppler probe was  utilized transthoracically toward the origin
of the left main coronary arteries of six weeks, two years, and
two years apolipoprotein-E null (ApoE−/−) atherosclerotic mice.
It  was  concluded that Doppler ultrasound combined with coronary
vasodilation via isoflurane could provide a  convenient and non-
invasive method to  estimate coronary reserve in  mice, but also that
care must be taken when assessing coronary flow in  mice under
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isoflurane anaesthesia because of its potent coronary vasodilator
properties.
Tomita et al. (2012) established the relationship between hemo-
dynamics and atherosclerosis in  aortic arches of ApoE−/− mice.
Mean flow velocities at the ascending and descending aorta (mVAA
and mVDA) were measured by Doppler ultrasound in wild type and
ApoE−/− male mice at three and nine months of age.
Another example of the use of ultrasonic imaging of cardiac
function was proposed by  Zhou et al. (2012).  In  their study, they
reported mitochondrial oxidative stress over a lifetime and con-
cluded that it causes aortic stiffening by inducing vascular wall
remodeling, intrinsic changes in  smooth muscle cell (SMC) stiffness
and aortic SMC  apoptosis (Zhou et al., 2012). Pulse wave velocity in
the heart was measured using Doppler with a 30 MHz  probe.
The study by Halade et al. (2011) suggested that rosiglitazone
RSG treatment has context dependent effects on cardiac remod-
eling and serves a  negative cardiac role when given with a corn
oil enriched diet. Mice were lightly anesthetized with isoflurane
(0.5–2%) and 2D  targeted M-mode echocardiographic recordings
were obtained. Dimensions and wall thickness of the LV were mea-
sured and fractional shortening was calculated.
Dopamine D3 receptor has a  critical role in  the emergence of
age related cardiac fibrosis, remodeling, and dysfunction (Johnson
et al., 2013). Animals underwent high-resolution echocardiogra-
phy using a 30 MHz transducer, in  experiment to assess the role of
Dopamine D3 on cardiac fibrosis.
2.6.3. Other applications
Ultrasound imaging plays a  role  in  kidney assessment of age-
ing mice (Springer et al., 2014). Using a  40 MHz linear array
transducer, high-resolution images were obtained in  a diversity
of pathologic lesions occurring within the abdomen of geriatric
mice with acquired hydronephrosis (Springer et al., 2014) that
enabled a determination of the underlying aetiology. Aetiologies
diagnosed from the imaging results include pyelonephritis, neo-
plasia, urolithiasis, mouse urologic syndrome, and spontaneous
hydronephrosis, and were confirmed at necropsy. This report
highlights the utility of high-frequency ultrasound for surveying
research mice for age-related pathology, and is  the first compre-
hensive report of multiple cases of acquired hydronephrosis in
mice. Moreover, it was recently demonstrated that preclinical high-
frequency US can be used to study the development of nonalcoholic
fatty liver disease (NAFLD) in  mice, with also potential therapeutic
implications (Fernandez-Dominguez et al., 2011).
2.6.4. Summary of advantages and limitations
The main advantages of ultrasound are: a) there is  no ionizing
radiation involved, b) it is  the fastest imaging modality, c)  the cost of
purchasing and operating the device is  the lowest, d) it is portable,
and e) easy to use. Echocardiography is  a  robust tool for assessing
cardiac (Abraham et al., 2007; Derumeaux et al., 2008; Friedberg
and Mertens, 2013; Halade et al., 2011; Hartley et al., 2007; Jackson
et al., 2012; Johnson et al., 2013; Rosenblatt-Velin et al., 2012;
Tomita et al., 2012; Zhou et al., 2012)  and kidney (Springer et al.,
2014) function in laboratory mice. Conventional echocardiographic
measurements, including chamber dimensions, wall thickness, and
ejection fraction are routinely obtained to assess cardiac function
in mice. Recently, myocardial strain and strain rate measurements
(Derumeaux et al., 2008) have  been added to  functional assess-
ments to provide additional details on regional abnormalities that
are not evident using conventional measurements. To date, all stud-
ies of strain and strain rate in  mice or rats have involved adult
animals. Myocardial ultrasound imaging in  mice is technically fea-
sible and has potential application in  studying the pathophysiology
of various cardiovascular and kidney disease.
The main limitations of this technique are  its user dependency
and the loss of accuracy for scanning some anatomical sites due to
poor penetration through air and bones.
2.7. Intravital microscopy
2.7.1. Technique
Intravital microscopy (IVM) is  an optical imaging technique that
enables live animal imaging at high spatial and temporal resolution.
Most commonly it utilizes the visible spectrum plus ultra-violet
and near-infrared wavelengths (∼300–1100 nm). IVM commonly
requires a surgical procedure to  access the tissue/organ of  inter-
est for microscopy, in which case the animal has to be  sacrificed
immediately after image acquisition. Most tissues are amenable to
this approach including, for example, intestinal mesentery, lung,
pancreas and skeletal muscles. Implantation of a dorsal skin fold
‘window’ chamber provides the ability to image the same tissue
in vivo repeatedly over days to  weeks (Intaglietta and Tompkins,
1973; Padhani et al., 2009; Papenfuss et al., 1979). Here, a  metal,
plastic or  carbon fibre chamber incorporating a  glass ‘window’
holds a  skin flap away from the mouse body to  enable placement
under a  microscope objective for transmitted light microscopy
(Fig. 5).
Dermal layers from one or both sides of the flap are surgi-
cally removed for optical clarity, exposing a  striated muscle layer
(panniculus carnosus) in the window. This technique also enables
implantation of tumour or other tissue/cells onto or into the
exposed muscle, resulting in tissue thicknesses of ∼100–300 m.
For instance, adipose tissue-derived microvascular fragments,
seeded onto porous polyurethane scaffolds, were implanted into
dorsal skin fold window chambers in  mice to study the effects of
ageing on  their vascularization (Laschke et al., 2014). For reflected
light microscopy e.g. epi-fluorescence, other types of ‘window’ can
be surgically implanted for exposing the underlying tissue (Alieva
et al., 2014). These include the cranial chamber (Monsky et al.,
2002),  mammary gland chamber (Shah et al., 2011), lung obser-
vation chamber (Hatakawa et al., 2002) and ‘body wall’ chamber
(Tsuzuki et al., 2001).
2.7.2. Vascular and cancer microcirculation applications
Most commonly, IVM is used to investigate vascular morphol-
ogy and function, stromal or parenchymal cell interactions with
blood vessels and gene expression using conventional wide-field
light microscopy, with either trans- or epi-illumination. Blood ves-
sels provide the greatest endogenous optical contrast amongst the
components of soft tissue enabling measurement of vessel length,
diameter and branching patterns without the need for exogenous
fluorescent contrast agents (Fig. 5). Red blood cell velocity can
also be measured, usually with the aid of fluorescently labeled
red blood cells or plasma. Methods involve the use of algorithms
that either track individual red cells (Reyes-Aldasoro et al., 2008a)
or measure the time difference between matched optical signals
received at different locations along flowing vessels (Fontanella
et al., 2013). Vascular permeability estimations made from mea-
suring the clearance kinetics of an intravenously administered
fluorescent contrast agent such as dextran are also valuable for
monitoring vascular integrity (Reyes-Aldasoro et al., 2008b). Micro-
circulatory abnormalities in  cancer, an age-related condition, have
been extensively studied using IVM (Lunt et al., 2010), for a  review.
The tumour vasculature is a  sought after therapeutic target and
IVM has played a  major part in progressing an understanding of
the processes involved in tumour vascularization and oxygenation
(Brizel et al., 1993; Gaustad et al., 2013; Kimura et al., 1996; Sorg
et al., 2005), metastasis (Beerling et al., 2011; Condeelis and Segall,
2003)  and response of tumour blood vessels to  vascular targeted
therapy (Akerman et al., 2013; Strieth et al., 2006; Vajkoczy et al.,
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Fig. 5. Intravital microscopy. A) an  implanted dorsal skin-fold window chamber in a  mouse; B)  a  mouse bearing a dorsal skin-fold window chamber is restrained in  a perspex
jig  for microscopy; the chamber is  immobilised beneath the  microscope objective; C)  tumour vasculature visualised by  intravenous administration of a  fluorescent contrast
agent  and multiphoton fluorescence microscopy; D) low power brightfield view of a tumour growing in a  window chamber; the eyelets of the circlip that keeps the glass
coverslip overlying the tumour in place can be seen out-of-focus E): tumour cells were labelled with Dendra2, a photo-switchable fluorophore; non-photoswitched are green
and  photo-switched are red; sequential imaging was used to  track the movement of the marked cells. Panel E  reprinted by permission from Macmillan Publishers Ltd: Nature
Methods, Kedrin et  al.,  5 (12): 1019–1021, copyright 2008, (Kedrin et al., 2008). (For interpretation of the references to color in this figure legend, the reader is referred to
the  web version of this article.)
1999), for example. Other ageing pathologies are strongly associ-
ated with microvascular defects and have been studied using IVM
in mice, for example in cerebral blood flow responses to neuronal
activation (Balbi et al., 2015), vasodilatory and microvascular den-
sity responses to  insulin, exercise and vascular endothelial growth
factor in skeletal muscle (Wagenmakers et al., 2015) and microcir-
culatory response to ischaemia in  skin (Harder et al., 2010).
2.7.3. Advances and other applications
Technical advances in  microscopy, cameras, fluorophores, com-
putation and image analysis methodology have meant that
applications for IVM, which has been a  research tool in  its basic
form for nearly a  century, are continually expanding. Microscopes
need to be adapted for live animal research to  incorporate facili-
ties for animal restraint or  anaesthesia and objective lenses with
sufficient working distances, magnifications and numerical aper-
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tures. Most IVM is performed with cooled CCD (charge-coupled
device) cameras and associated hardware that can achieve around
90% quantum efficiency at video rate. Confocal microscopy, often
incorporating spinning disc technology or video-rate laser scanning
for fast image capture, or multi-photon fluorescence microscopy
(Fig. 5)  are now commonly used for IVM (Beerling et al., 2011;
Brown et al., 2001; Tozer et al., 2005). As  well as enabling 3-D
imaging, these techniques circumvent the degradation of image
quality from light scattered by out-of-focus tissue. This problem
can be significant for conventional microscopy even in the thin
tissue exposed in window chamber preparations. Multiphoton flu-
orescence microscopy has the added advantages of increased tissue
penetration of the long wavelength light used (from ∼40–100 m
for confocal to several hundred m for multiphoton) and reduced
photo-bleaching and photo-toxicity (i.e. confined to the focal
plane). Multi-photon fluorescence microscopy has been used, for
example, to study the effect of ageing on the fate of haematopoietic
stem cells in the marrow of long bones (Kohler et al., 2009). Hyper-
spectral imaging incorporates an optical filtering system in front of
the IVM camera, enabling capture of multiple images at different
visible light wavelengths, which is  particularly useful for measure-
ment of blood haemoglobin oxygen saturation, for example (Shonat
et al., 1997; Sorg et al., 2005). Optical coherence tomography (OCT)
uses light scatter to generate image contrast and so is  distinct from
other forms of optical microscopy (Fercher et al., 2003). It can be
likened to ultrasound imaging as it measures the intensity and
timing of back-scattered light instead of sound. Use of long wave-
length light, typically 800–1300 nm enables relatively good depth
penetration that can exceed 1 mm.  Functional extensions to  OCT,
primarily Doppler and speckle-variance techniques for monitor-
ing microvascular blood flow (Barton and Stromski, 2005), have
extended the utility of OCT in  intravital studies.
Use of fluorescent probes is  a mainstay for bio-imaging in  intrav-
ital preparations. Conventional organic dyes such as isothyocyanate
(FITC) (excitation and emission maxima at 488 and 520 nm respec-
tively) are prone to photo-bleaching but  still widely used for image
contrast either alone or conjugated to  proteins of interest. Chem-
ically sensitive derivatives of FITC enable investigations of tissue
pH for example and the phosphorescence life-times of various por-
phyrin derivatives are oxygen-sensitive (Helmlinger et al., 1997).
Newer synthetic dyes such as Alexa-fluors and certain fluorescent
nano-crystals (quantum dots) have improved photostability and
emission characteristics. Fluorescent proteins (originally green flu-
orescent protein, GFP, but  now expanded to many different types
with superior properties) have been applied widely for IVM, pri-
marily as reporters of gene expression and for cell tracking but  also,
more recently, for probing molecular interactions via FRET (Förster
Resonance Energy Transfer) (Condeelis et al., 2000; Conway et al.,
2014; Erami et al., 2015). Amongst these proteins are ones that
experience reversible or irreversible changes to  their emission
spectra on exposure to specific wavelengths, which may  include
changes in both intensity (photo-activated, Fig. 5) and emission
wavelength (photo-switchable). Use of these recently developed
fluorescent proteins are not fully explored for IVM as yet but there
is clear potential for their use in tracking different cell populations
over time (Kedrin et al., 2008; Pittet and Weissleder, 2011).
2.7.4. Summary of advantages and limitations
Intravital microscopy enables highly sensitive in vivo imaging
of tissue structure and function at high spatial resolution (cellu-
lar and sub-cellular) and at relatively low cost. There are many
suitable fluorescent probes available, with increasingly sophisti-
cated properties, and the technique is  amenable to  use of gene
reporters. Use of  near-infrared (NIR) probes reduces the problem
of depth penetration. However, there are  some fundamental lim-
itations of IVM, which are not overcome by  modern techniques,
notably the necessity for surgery. In addition, where window cham-
bers are  used, abnormally high tissue pressures may  be induced.
Temperature control, toxicity of contrast agents, photo-toxicity and
immune reactions are also important considerations. Quantifying
IVM data at high spatial resolution and developing analytical meth-
ods for deriving accurate descriptions of biological functions are
on-going challenges, especially with the vast amounts of imaging
data that  are  now routinely produced and fundamental difficulties
associated with quantifying light emission/absorption. Window
chambers have been modified for use with MRI  scanners (Gaustad
et al., 2008)  and simultaneous application of IVM with other imag-
ing  modalities such as MRI  and PET provides an opportunity to
exploit the best of each modality.
2.8. Whole body optical imaging
2.8.1. Technique
Whole body optical imaging is based on the excitation of  flu-
orochromes by means of an external light source (fluorescence)
or  on the light emitted by chemiluminescent enzymatic reactions
within the subject (bioluminescence). In both imaging modes, a
CCD camera is  used to acquire the light signal, most commonly
in  a  2D planar image. The camera can be  cooled down in order to
increase its sensitivity to light and therefore acquire weaker signals
(Willmann et al., 2008). Typical fluorochromes used are green flu-
orescent protein (GFP), red fluorescence protein (RFP), rhodamine,
or engineered fluorochromes for particular applications (see Sec-
tion 2.7). Near-infrared (NIR) fluorescent proteins have allowed
significant improvements in  tissue penetration for in vivo imag-
ing (Hassan and Klaunberg, 2004)  and avoidance of artifacts from
tissue auto-fluorescence (Kovar et al., 2007).
2.8.2. Cancer research
Whole body optical imaging is a  sensitive technique but, due to
light scattering, spatial resolution is poor. In mouse models, GFP
has been used to measure the in vivo growth of many different
types of tumours, as well as metastatic spread and the effect of
drug treatments on tumour growth (Hoffman, 2001). Moreover,
genetically engineered light-emitting reporter genes can be used
to study in vivo protein expression in cancer models and the effect
of pharmacological treatments (Willmann et al., 2008). There is  a
vast literature about optical fluorescence imaging applications for
studying cancer; we  report here only a few examples. Chen et al.
(2003) used a  glucose analogue with NIR fluorescence to local-
ize tumours in  mice via their high rate of glycolysis compared
to surrounding normal tissue. In another application Citrin et al.
(2004) labeled endostatin with indocyanine dye (Cy5.5) for detect-
ing  tumour vasculature. Pesnel et al. (2012) used a  monoclonal
antibody labeled with a  NIR fluorochrome for detecting leukemic
foci  in  a  disseminated murine model.
2.8.3. Other applications
GFPs have been used, amongst other fluorescent proteins, for
studying gene expression and protein-protein interactions (van
Roessel and Brand, 2002), viral infection (Haan et al., 2001),
embryonic development (Lipp and Muller, 2004) and in neuro-
science (Cruz-Martin and Portera-Cailliau, 2014). In thrombosis
mouse models, NIR fluorochromes conjugated to a  thrombin-
specific oligopeptide substrate (Jaffer et al., 2002)  or conjugated
to a  peptide ligand derived from the amino terminus of alpha2-
antiplasmin (Jaffer et al., 2004) have been used in order to  image
experimental thrombi. NIR proteins have also been used in  muscu-
loskeletal applications. For example, Hansch et al. (2004) showed
that anti-F4/80 monoclonal antibodies labeled with Cy5.5 can be
used to image antigen-induced rheumatoid arthritis in  mice. In
addition, a  cathepsin-B NIR probe showed potential for diagnosis
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of  early osteoarthritis (Lai et al., 2004) and a  protease-activated
NIR probe was used for early monitoring of treatment response to
antirheumatic drugs (Wunder et al., 2004). For  other applications,
Wolf et al. (2014) used redox-sensitive GFP for studying oxidative
stress in the skin of mice in vivo. Hall et al. (2012) used a  dynamic
multi-wavelength optical imaging system for visualizing physio-
logically relevant levels of superoxide in specific brain regions,
which can be used to study obesity, diabetes, hypertension and the
ageing process itself.
2.8.4. Summary of advantages and limitations
Whole body optical imaging is  easy to perform, fast and cost
efficient compared to PET or MRI  for example.
The main limitation is low depth penetration (a few mm  in
the case of visible dyes) and light scattering, which severely lim-
its spatial resolution to the order of 1–10 mm.  It is these issues
that necessitate the use of intravital microscopy (Section 2.7) for
many optical imaging applications. While NIR fluorochromes have
improved penetration for in vivo applications (up to several cen-
timetres (Kovar et al., 2007)), dense tissues such as bones still
represent a problem. While most applications are 2D, 3D systems
are now available, providing much better locational information
(Zhang et al., 2013). The cost effectiveness of whole body optical
imaging makes it easy to combine with other in vivo imaging modal-
ities such as micro-CT (Barrefelt et al., 2015; Bernthal et al., 2014;
Niska et al., 2012)  and preclinical-MRI (Bakalova et al., 2015).
3. Considerations in using in vivo imaging for studying
ageing with mice models
3.1. Standardization and three Rs (reduction, refinement and
replacement) of animals in experimental research
Animal experiments are  inherently complex (Denayer et al.,
2014). Standardized in vivo imaging may  present an opportunity
to monitor aged mice more effectively. Several sets of stringent
guidelines, such as the “Animal Research: reporting of in vivo exper-
iments (ARRIVE)” guidelines and the “Guidelines for the welfare
and use of animals in  cancer research” are  useful for making exper-
imental procedures involving animals more robust (Kilkenny et al.,
2010; Workman et al., 2010). Using guidance from ARRIVE, the
international mouse phenotyping consortium uses both male and
female animals in  all phenotyping studies to account for sexual
dimorphism. With the increasing robustness of in vivo imaging,
it may  become a  fundamental add-on to the current procedures
for disease phenotyping in  addition to procedures that determine
the endpoints and effects of interventions, such as body weight
(Dennis, 2000; Hawkins et al., 2011; Morton, 2000). So far, it is  very
difficult to standardize techniques, measurements and laboratory
environments across laboratories. Therefore, despite producing
good quality data, studies between research groups are often not
comparable due to a lack of a consensus regarding standardization
(Hrabe de Angelis et al., 2015; Richter et al., 2009; van der Staay
et al., 2010). Obviously, this results in increased animal usage and
wastes resources when studies produce conflicting results. With
aged mice representing such a costly investment for laboratories,
it will also become even more important for these studies to be
efficient, well planned and maximized in  a  way that obtains the
most possible benefit from each animal. In vivo imaging inherently
maximizes the use of animals due to  its non-terminal nature. More-
over, in vivo imaging techniques can be combined with other in vivo
assessments, which can maximize the usefulness of the mice taking
part in these studies. For example, traditional in vivo measurements
can be used to assess a  range of factors, as reported in  life methods
employed by the IMPC in their International Mouse Phenotyping
Resource of Standardised Screens and The European Mouse Phe-
notyping Resource of Standardised Screens (Mallon et al., 2008),
such as behaviour, body composition and frailty (Whitehead et al.,
2014).
Maximal use of any available techniques for the reduction,
replacement and refinement of animal experiments should be a
priority for any researcher working with animals (Festing, 2004;
Parker and Browne, 2014). In vivo imaging, having the potential
for reducing measurement variability by tracking the same animal
longitudinally when compared to standard cross-sectional design,
can reduce animal numbers. In vivo imaging measurements are also
capable of refining animal experiments as in some cases they can
reduce pain, suffering, distress and lasting harm that may  be expe-
rienced by the animals using other methods. Additionally, better
end point evaluation and health measures will increase the qual-
ity of animal experiments, increase animal welfare and hopefully
reduce the requirement to repeat experiments.
3.2. Animal considerations in longitudinal in  vivo imaging with
age
Although the imaging modalities presented in this review
offer great potential for longitudinal studies, there are still
some challenges in their application to mouse models such as
complexity of animal monitoring (preclinical-MRI), radiation expo-
sure from the scan (micro-CT) or from the radioactive markers
(preclinical-PET and -SPECT), and invasiveness of the procedure
(intravital microscopy). Animal considerations when using longitu-
dinal in vivo imaging in preclinical research have been extensively
reviewed for young and adult animals (Hildebrandt et al., 2008;
Tremoleda et al., 2012). However, little is  known about the extent
ageing may  have as a  confounding factor. With age, we  observe
a  decline in major physiological functions, including cognitive
(Shoji et al., 2016), cardiovascular (Dai and Rabinovitch, 2009),
and respiratory (Lowery et al., 2013), an impaired ability to
repair stress-induced damage at the cellular level (Kourtis and
Tavernarakis, 2011), an altered metabolic footprint (Houtkooper
et al., 2011)  and thermoregulation (Van Someren, 2007), and an
increased level of sensitivity to stress inducers (Shoji et al., 2016).
Therefore, special considerations may  apply when using these
modalities on aged animals, some of which are reported below.
3.2.1. Animal handling
Regardless of the imaging modality, the stress associated with
handling of the animals in  laboratory routines, preparation for
imaging (e.g. restraint, injections, surgeries) and the imaging itself
creates physiological and metabolic modifications (Meijer et al.,
2005, 2006). These changes can affect experimental outcomes,
especially in longitudinal settings (i.e. repeated handling) where
different measurements are performed on each mouse at each time
point (i.e. scans with different techniques). The capacity adult mice
have to  cope with stress induced damage, associated with care-
ful monitoring ensures minimal effect of handling. However, in
aged mice, because they present an impaired ability to  cope with
stress, appropriate controls and validations must be carried out to
ensure these changes have minimal effects on the outcome of  the
experiment.
3.2.2. Anaesthesia
Although required to  facilitate immobilisation and image acqui-
sition, anaesthesia is accompanied by a  depression in  respiration
rate, heart rate and cardiac output, and a  decrease in  core temper-
ature (Caro et al., 2013). These changes result in decreased speed
of oxygen delivery to tissues, increasing risk of hypoxia. This risk
is aggravated with age, as oxygen delivery to  the tissues declines
(North and Sinclair, 2012), along with respiratory and cardiac func-
110 E. Dall’Ara et al. /  Mechanisms of Ageing and Development 160 (2016) 93–116
tions, thus affecting recovery. Therefore, extra care  must be given
to aged animals, in  terms of monitoring pre- and post-imaging,
especially in longitudinal settings. For instance, using inhalation
anaesthesia (such as Isoflurane) mixed with medical grade oxy-
gen will help to reduce the risk of hypoxia related to anaesthesia.
It will also allow individual responses to anaesthesia to be effi-
ciently monitored. The animal’s temperature should also be  kept
constant during imaging (e.g. with hot air or heating pads). Finally,
while adult mice can withstand several hours of anaesthesia with-
out apparent short-term effects (Lu et al., 2015b), anaesthesia time
should be decided and tested on aged animals to minimise inter-
ferences with the experimental outcomes.
3.2.3. Radiation dose
Whether the exposure is intrinsic, when radiotracers are
injected for Micro-PET imaging, or is extrinsic, as it is in micro-
CT imaging, radiation exposure is  a  potential limitation of these
methodologies. Irradiation is known to  cause DNA damage, which
is repaired in a couple of days in  adult mice (Grudzenski et al., 2010).
When longitudinal studies are planned, a  compromise between
image quality and radiation dose is often reached. This compromise
may  be more delicate to establish when studying aged mice, as the
tissues ability to repair DNA damage declines with age (Grudzenski
et al., 2010). The scanning time as well as the time interval between
two imaging sessions should therefore be carefully decided to  min-
imise the radiation related effects.
3.2.4. Animal frailty
The ageing process is  accompanied by a  frailty state that makes
the animal more sensitive to external stimuli such as exposure
to handling stress or  to radiation. Frailty might be  exacerbated in
longitudinal settings and it is  therefore essential to monitor the
wellbeing of the animal throughout the experiment and report
any changes. This monitoring can be non-invasive and fast, using
a recently published approach that  quantifies the frailty index for
each animal (Whitehead et al., 2014).
3.2.5. Age of the mouse models
The reviewed literature about applications of in vivo imaging
modalities for studying ageing and age-related disorders (Table 2)
revealed that most of the mice models were used in  their adult-
hood (less than 12 months old), during which all physiological
processes are healthy and all markers of ageing (e.g. DNA damage,
oxidative stress, inflammatory cytokines and cellular senescence)
(Lopez-Otin et al., 2013) are absent or minimal. This  means that
although the current models provide precious information on the
diseases onset and progression, they might underestimate ageing
as a confounding factor. It  is therefore recommended to use aged
mice, yet to carefully choose the age window for each project, and
take extra care when using very old mice, as they present a  high
frailty index, and numerous tissue dysfunctions that may  be unre-
lated to the study and interfere with the outcome of the experiment
by increasing the variability in the data (Miller and Nadon, 2000).
4. Conclusions
Aged mouse models are a  powerful tool that can be used to bet-
ter understand the ageing process. However, the novelty of these
mouse models will also pose new challenges to  researchers in var-
ious forms including phenotyping and endpoint evaluation. State
of the art in vivo imaging on aged mice enables well-controlled and
accurate longitudinal measurements of tissue and organ pheno-
types associated with healthy ageing and age-related diseases. It
is also possible to combine different imaging techniques, in order
to study dysfunction of multiple tissues or the effect of certain
pathologies or treatments on different systems. Combining in vivo
imaging with other in vivo methodologies will also help to max-
imise the data gained from individual mice.
4.1. Future work and perspectives
It has become clear that the single imaging modalities pre-
sented in this review have the potential to be combined with each
other and with other standard laboratory techniques, in order to
exploit the best features of each modality. The standardization
of spatial and temporal measurement from such complex tech-
niques is  necessary in  order to  provide reliable and sharable data.
Central facilities that contain all the different imaging techniques
and expert researchers with multidisciplinary skills (e.g. biology,
physics, engineering) to run them and interpret the data obtained
are highly desirable. Besides providing novel research findings,
these in vivo techniques will also help with the reduction of animal
usage and refinement of techniques.
A number of challenges remain to be  addressed, regarding both
the individual techniques and combinations thereof. A lot of  work
needs to  be  done on animal handling protocols during scanning
in vivo,  e.g. to  reduce anaesthesia artifacts, and on the design of
optimal instrumented animal holders and chambers that can be
used in all systems. In particular, specific standardized procedures
should be defined for handling aged mice, showing signs of  frailty
and dysfunction of multiple tissues. Another point that should be
considered is  the evaluation of the true non-invasiveness of the
imaging modalities. This requires more methodological work, in
order to  investigate how much each modality affects the measure-
ments being made; for example, the use of contrast agents at high
concentrations in  MRI, or the use of foreign proteins for molecular
imaging studies. A  further challenge is  related to  image analyses
and merging of data obtained from multi-modality imaging into
a single dataset. Due to unavoidable deformation of soft tissues,
standard rigid and affine registrations are  probably not sufficient
and application of nonlinear registration algorithms becomes fun-
damental.
Overall, multi-modality in  vivo imaging in mouse models has
the potential of providing biomarkers fundamental to  investigate
the ageing mechanisms and the effects of dysfunction of  multiple
tissues and organs and systems.
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